Back to search results

LLS Services Impact on Outcomes and Care for Blood Cancers

This study is looking at how services from the Leukemia and Lymphoma Society (LLS) affect people with blood cancers like leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN). You might be able to join if you are 18 or older, have one of these blood cancers, and are receiving or planning to receive treatment. The study wants to see if LLS programs, which include things like co-pay help, transportation assistance, and peer support, can improve access to care and reduce medication problems. The study is currently unclear on its enrollment status and aims to include 400 participants.

Study design
This is an interventional study with a planned enrollment of 400 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will receive LLS's free patient and caregiver services virtually. Your care needs and medication access will be measured at the start, after 3 months, and after 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 6 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05745285

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Recruiting
NAAges 18+InterventionalSupportive care
University of Miami
~400 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:LLS Program

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in number of care needs as measured by the Access to Care Survey
Measured over Baseline, 3 month, 6 month
+1 more outcome measured

Conditions

Leukemia
Lymphoma
Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasm

Explore related trials

LeukemiaLiquid TumorLymphomaMultiple MyelomaMyelodysplastic SyndromeMyeloproliferative Neoplasm

Where it's being run

3 sites across 3 states
Florida1
Illinois1
Texas1

Study leadership

  • Frank Penedo, PhD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

Carlos Melara, MD
[email protected]
3052438300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN).
Have received, be receiving, or be planning to receive primary or relapse treatment for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) and meet at least one of the following criteria:
Be currently receiving treatment which started within the past 18 months OR
Be planning to start treatment within one month OR
Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.
Not be currently participating in any LLS programs or services
Be willing to be followed for 6 months
Speak English or Spanish

Exclusion

Are not diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)
Do not meet at least one of the following criteria if treated or planning to get treated for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN):
Be currently receiving treatment which started within the past 18 months OR
Be planning to start treatment within one month OR
Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.
Are currently participating in any LLS programs or services
Are not willing to be followed for 6 months
Do not speak English or Spanish.

What this trial measures

  • Change in number of care needs as measured by the Access to Care SurveyBaseline, 3 month, 6 month

    Change in number of care needs will be assessed via the self-report Access to Care Survey which includes access to primary and specialty care, access to medications specific to cancer care, and access to financial resources specific to cancer care. The survey uses a composite score to assess participants' needs. Scores range from 0 to 21 with lower scores indicating better access to care needs.

  • Change in number of medication access problems as measured by the Access to Care SurveyBaseline, 3 month, 6 month

    Change in number of medication use will be assessed via the self-report Access to Care Survey which includes access to medications specific to cancer care. The survey uses a composite score to assess participants' medication use. Scores range from 0 to 6 with lower scores indicating better access to medication.